Announcements Trials
Browse Landscape

Phase

Phase NA 34Phase 2 3Phase EARLY_PHASE1 2Phase 3 2Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Screening 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Genetic Testing × Clear all
NCT06058377 2026-05-27

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT03233191 2026-05-05

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
108,508 enrolled
Breast

Breast Screening

Data powered by HemOnc (CC BY 4.0) Colophon âš¡